|
Developed by
|
Supported by
|
|
Queen's University Belfast Originator
https://www.qub.ac.uk/
United Kingdom Queen's University Belfast (QUB) is a historic public research institution located in the heart of Belfast, Northern Ireland. Founded in 1845, it is a member of the elite Russell Group of research-intensive universities and was recently named the UK University of the Year 2026 by the Good University Guide. The university is globally celebrated for its architectural beauty, most |

(A–G) Reservoir-type DPV implants (A) solid DDU-4320 core and no end sealing; (B) solid DDU-4320 core with end sealing. (C–G) Implants having liquid Kolliphor®
https://pureadmin.qub.ac.uk/ws/files/692767915/Wang2026b.pdf

Structure of Dapivirine (DPV)
https://pubchem.ncbi.nlm.nih.gov/substance/135129476#section=2D-Structure

Schematic graphical representation of DPV subdermal implant and the plasma concentration-time curve
https://pureadmin.qub.ac.uk/ws/files/692767915/Wang2026b.pdf

Schematic of the DPV release mechanism from reservoir-type implants
https://pureadmin.qub.ac.uk/ws/files/692767915/Wang2026b.pdf
Polymeric implant
Transdermal
Dose: 72-91 mg dapivirine per implant
91 mg per implant
No clinical dosing regimen has been established yet
Not provided
Not provided
Not provided
Not provided
Not provided
Dapivirine implants were manufactured by dispersing DPV in silicone elastomer, filling medical-grade silicone tubing to form a drug reservoir, curing the formulation, and sealing the implant ends. Optimised designs incorporated Kolliphor® EL liquid cores or dip-coated silicone membranes to enhance release. Quality testing included dimensional analysis, drug loading verification, DSC characterisation, and long-term in vitro release studies. Materials needed: 1) Micronised DPV 2) Translucent platinum-cured silicone elastomer tubing 3) Polyvinyl chloride tubing 4) Kolliphor® EL 5) Tween® 80
Waters Alliance e2695 High-performance liquid chromatography (HPLC) system coupled with a 2489 UV/Visible detector
Not provided
Kolliphor EL (Cremophor EL)
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL
Wang S, Murtadha RZ, Malcolm RK. Subdermal implants for HIV prevention with increased dapivirine release rates. J Control Release. 2026;373:700-711. doi:10.1016/j.jconrel.2026.08.040.
Siqi Wang — International Journal of Pharmaceutics — 2026-05-19
Link: https://pureadmin.qub.ac.uk/ws/files/692767915/Wang2026b.pdf
Dapivirine (DPV) is an antiretroviral drug used for prevention of sexually acquired HIV infection in the form of a monthly matrix-type silicone elastomer vaginal ring. As part of efforts to develop longer acting antiretroviral products for HIV pre-exposure prophylaxis (PrEP), we previously reported reservoir-type DPV-releasing silicone elastomer subdermal implants. These early prototypes were constrained by relatively low DPV daily release rates (7–14 µg/day), which are likely too low to prevent sexual transmission of HIV. Here, we report in vitro formulation development of next-generation implant formulations as part of efforts to increase DPV release rates. Three strategies were evaluated—(i) reservoir-type implants fabricated from medical-grade silicone tubing comprising a core containing DPV solubilised in a liquid polyethoxylated castor oil (Kolliphor® EL), (ii) dip-coated reservoir rods, comprising a matrix-type silicone core and a relatively thin (∼0.33–0.66 mm) drug-free, silicone elastomer, rate-controlling membrane applied by dip coating, and (iii) simple matrix-type silicone elastomer rods. Replacing the conventional silicone elastomer core of the implants with Kolliphor® EL increased DPV solubility and enhanced steady-state flux ∼1.5-fold. Dip-coated implants provided mean daily release rates of 19–41 µg/day. Matrix-type implants lacking a rate-controlling membrane delivered up to 185 µg/day. While these release rates represent a substantial improvement over first-generation devices, it remains uncertain whether they would produce systemic concentrations sufficient for HIV prevention, given dapivirine’s relatively low potency and the absence of a local delivery advantage with subdermal administration. Nonetheless, the findings are useful in demonstrating the feasibility of designing silicone-based implants, illustrating how core composition, membrane geometry, and release conditions influence DPV release from silicone subdermal implants, and providing a basis for future in vivo pharmacokinetic and preclinical evaluation.
Wang S, Murtadha RZ, Malcolm RK. Formulation development of a dapivirine-releasing subdermal implant for HIV prevention. International Journal of Pharmaceutics. 2026;629:123409. doi:10.1016/j.ijpharm.2026.122409
Siqi Wang — International Journal of Pharmaceutics — 2025-12-19
Link: https://www.sciencedirect.com/science/article/pii/S0378517325013614
There have been several significant advances in recent years around long-acting strategies for HIV pre-exposure prophylaxis, including DapiRing® (a 1-month dapivirine (DPV)-releasing vaginal ring), Apretude® (a cabotegravir intramuscular injection administered every two months), and Yeztugo® (a twice-yearly lenacapavir injection). With the goal of developing new drug delivery devices that can extend antiretroviral release for 12 months or longer, we report here our preliminary efforts to design a subdermal implant releasing the antiretroviral drug DPV. These reservoir-type rod implants (length 40 mm, cross-sectional diameters 2.5, 3.2, 3.5 or 4.0 mm) comprised a silicone elastomer core containing solid crystalline DPV (loading 10, 20 or 40 % w/w) and an open-ended non-medicated rate-controlling silicone elastomer membrane (thickness 0.5, 0.8 or 1.0 mm). DPV in vitro release rates could be modulated by adjusting the membrane thickness. Continuous in vitro DPV release ∼12 μg/day was demonstrated over 330 days, with sufficient residual drug content (∼87 mg/∼95 %) to extend release for at least 5 years. In particular, the study highlights the challenges in designing subdermal implants providing sufficient DPV release to maintain systemic/vaginal concentrations at protective levels.
No documents were uploaded
There are no additional links